Natco Pharma Limited (NATCOPHARM)
Investor Presentation
Investor Presentation - August 2026
- FY26 global revenues INR 43,759 Mn; strong double-digit growth over past decade
- Key segments: Export formulations INR 32,345 Mn, Domestic formulations INR 4,409 Mn, API INR 2,347 Mn, Crop Health Sciences INR 1,382 Mn
- Q1FY27 revenue INR 7,944 Mn; EBITDA margin 30.9%; PAT INR 2,065 Mn
- Focus on complex, limited competition molecules and expanding US, Canada, Brazil, and RoW markets
- Crop Health Sciences division demerger approved by Board, targeting value unlocking
- Investments in cell & gene therapy and xenotransplantation with clinical trials starting 2027
- Strong R&D with 2 centers, 500+ scientists, and 45 active US DMFs
- Expanding presence in Africa via Adcock Ingram stake acquisition
- Strategy includes therapy diversification and advanced therapeutics pipeline
- Consolidated net worth INR 92,211 Mn; ROE 15.4%, ROCE 15.9% for FY26
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 NATCOPHARM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add NATCOPHARM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Natco Pharma Limited
Important.
The summary above is generated automatically from Natco Pharma Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.